These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34738623)

  • 1. Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF‑κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis.
    Ding D; Yan J; Feng G; Zhou Y; Ma L; Jin Q
    Int J Mol Med; 2022 Jan; 49(1):. PubMed ID: 34738623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-κB/ERK signaling pathway.
    Guo H; Ding D; Wang L; Yan J; Ma L; Jin Q
    PLoS One; 2021; 16(12):e0261127. PubMed ID: 34914744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorption.
    Ding D; Wang L; Yan J; Zhou Y; Feng G; Ma L; Yang Y; Pei X; Jin Q
    PLoS One; 2022; 17(7):e0271485. PubMed ID: 35900969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sotrastaurin, a PKC inhibitor, attenuates RANKL-induced bone resorption and attenuates osteochondral pathologies associated with the development of OA.
    Pang C; Wen L; Qin H; Zhu B; Lu X; Luo S
    J Cell Mol Med; 2020 Aug; 24(15):8452-8465. PubMed ID: 32652826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesoid X receptor agonist attenuates subchondral bone osteoclast fusion and osteochondral pathologies of osteoarthritis via suppressing JNK1/2/NFATc1 pathway.
    Hu W; Cai C; Li Y; Kang F; Chu T; Dong S
    FASEB J; 2022 Apr; 36(4):e22243. PubMed ID: 35224782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells.
    Nikhil K; Sharan S; Roy P
    Pharmacol Rep; 2015 Dec; 67(6):1264-72. PubMed ID: 26481551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti‑osteoclastogenic effects of
    Sim JS; Lee HY; Yim M
    Mol Med Rep; 2022 Nov; 26(5):. PubMed ID: 36082821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroartemisinin attenuates osteoarthritis by inhibiting abnormal bone remodeling and angiogenesis in subchondral bone.
    Ma L; Zhao X; Liu Y; Wu J; Yang X; Jin Q
    Int J Mol Med; 2021 Mar; 47(3):. PubMed ID: 33448319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
    Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
    Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rebamipide Attenuates Mandibular Condylar Degeneration in a Murine Model of TMJ-OA by Mediating a Chondroprotective Effect and by Downregulating RANKL-Mediated Osteoclastogenesis.
    Izawa T; Mori H; Shinohara T; Mino-Oka A; Hutami IR; Iwasa A; Tanaka E
    PLoS One; 2016; 11(4):e0154107. PubMed ID: 27123995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
    Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
    Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
    Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
    Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
    Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
    Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
    Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
    Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroartemisinin represses osteoclastogenesis of bone marrow macrophages through reduced NFATc1 expression and impaired phosphorylation of IκBα.
    Komaki S; Sakai E; Fukuma Y; Nishishita K; Okamoto K; Tsukuba T
    Biomed Res; 2018; 39(4):169-177. PubMed ID: 30101837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amiloride inhibits osteoclastogenesis by suppressing nuclear factor-κB and mitogen-activated protein kinase activity in receptor activator of nuclear factor-κB-induced RAW264.7 cells.
    Wang X; Zhu Y; Zheng S; Ni C; Zhao L; Liu C; Chen A; Xiao J
    Mol Med Rep; 2015 May; 11(5):3451-6. PubMed ID: 25592168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.